Abstract
Pathological endpoints such as tumour size, lymph node status and vascular invasion remain the most useful guides in selecting treatment strategies for breast cancer. There is a need, however, to further investigate the molecular mechanisms that determine the properties of an individual tumour e.g., hormone responsiveness and probability of metastasis. While numerous prognostic factors have now been identified few have contributed to defining clinical response to therapy. Oestrogen-regulated genes are likely to be important since they not only define a functional oestrogen receptor, but alterations in their expression might provide insights into the mechanisms involved in tumour progression and loss of endocrine sensitivity. Recently an oestrogen responsive gene, pLIV1, has been isolated and shown to be expressed in ER+ disease where it appears to predict nodal involvement. The present paper describes aspects of its regulation and discusses the potential role of this and other genes in the development of endocrine resistance.
References
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G GranataG Di Fronzo
Nov 1, 1990·Molecular Endocrinology·B van der BurgS W de Laat
Jul 14, 1989·Biochemical and Biophysical Research Communications·C S LeeR L Sutherland
Oct 1, 1988·Molecular and Cellular Endocrinology·D L ManningC D Green
Mar 25, 1988·Nucleic Acids Research·V CavaillesH Rochefort
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M C RioP Chambon
Dec 20, 1982·Nucleic Acids Research·P MasiakowskiP Chambon
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D L ManningR W Blamey
May 1, 1993·Journal of Cellular Biochemistry·C J OrmandyR L Sutherland
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D L ManningR I Nicholson
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D L Manning, R I Nicholson
Citations
Jan 1, 1996·Breast Cancer Research and Treatment·R A McClellandR I Nicholson
Feb 19, 2009·Breast Cancer Research and Treatment·Christopher L TebbitJohn A Olson
Mar 12, 2008·Molecular Biology Reports·Hui ShenJunsheng Guo
Feb 13, 2001·Molecular and Cellular Endocrinology·B MadsenJ Fahrenkrug
Feb 13, 2001·The Journal of Steroid Biochemistry and Molecular Biology·P J KushnerP Webb
Oct 25, 2011·PloS One·Anna Dvorkin-Gheva, John A Hassell
Nov 24, 2011·PloS One·Hui-Wen LueLeland W K Chung
Aug 4, 2007·Molecular Medicine·Kathryn M TaylorRobert I Nicholson
Aug 2, 2012·Nutrients·Bruce J Grattan, Hedley C Freake
Feb 22, 2008·Nutrition Reviews·Cathy W Levenson, Rikki C Somers
Apr 30, 1996·Annals of the New York Academy of Sciences·R I NicholsonC K Osborne
Jan 23, 2009·Journal of Cellular Biochemistry·Renty B Franklin, Leslie C Costello
Feb 28, 2009·Trends in Molecular Medicine·C HogstrandK M Taylor
Dec 24, 2016·Pharmaceuticals·Adam J Johnson, Ming J Wu
Jan 9, 2004·International Journal of Cancer. Journal International Du Cancer·Neil K RushmereRobert I Nicholson
Jun 21, 2001·Endocrinology·R A McClellandR I Nicholson
Sep 5, 2019·Metallomics : Integrated Biometal Science·Silvia ZiliottoKathryn M Taylor
Feb 19, 2002·Oncogene·Pankaj SethKornelia Polyak
Nov 22, 2008·Biochemical Society Transactions·Kathryn M Taylor
Mar 28, 2003·Biochimica Et Biophysica Acta·Kathryn M Taylor, Robert I Nicholson